[Modern treatment of parkinsonism].
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001933:Brain Stem / Q000032:analysis; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use; D004298:Dopamine / Q000032:analysis; D004357:Drug Synergism; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced; D009638:Norepinephrine / Q000032:analysis; D010300:Parkinson Disease / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000188:drug therapy / Q000209:etiology; D012701:Serotonin / Q000032:analysis; D014364:Tryptophan / Q000627:therapeutic use
D000978:Antiparkinson Agents; D006834:Hydrazines; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D014364:Tryptophan; D004298:Dopamine; D009638:Norepinephrine
Die moderne medikamentöse Behandlung des Parkinsonismus.